Are Alcohol Anti-relapsing and Alcohol Withdrawal Drugs Useful in Cannabinoid Users?
Patrycja Kleczkowska, Irena Smaga, Malgorzata Filip, Magdalena Bujalska-Zadrozny
Neurotoxicity Research November 1, 2016 DOI: 10.1007/s12640-016-9655-z (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Keywords | Alcohol abstinence Alcohol withdrawal drugs Cannabinoid Interactions |
| Key findings | Cannabinoids are often taken together with medications for alcohol use disorder and alcohol withdrawal syndrome, and recent advances in knowledge of their interactions are summarized. |
Abstract
Cannabinoids are still classified as illegal psychoactive drugs despite their broad and increasingly acknowledged therapeutic potential. These substances are most famous for their wide recreational use, particularly among young adults to either alter the state of consciousness, intensify pleasure induced by other psychoactive substances or as an alternative to the previously abused drugs. It is important to emphasize that cannabinoids are often taken together with a variety of medications intended for the treatment of alcohol use disorder (AUD) or alcohol withdrawal syndrome (AWS). These medications include disulfiram, acamprosate, and naltrexone. In this paper, we summarize recent advances in the knowledge of possible beneficial effects and interactions between cannabinoids and drugs commonly used for treatment of AUD and AWS either comorbid or existing as a separate disorder.
Citations in the library
Cites 8
- Separate and combined effects of the GABAA positive allosteric modulator diazepam and Δ⁹-THC in humans discriminating Δ⁹-THC. Drug and Alcohol Dependence October 1, 2014
- Naltrexone does not attenuate the effects of intravenous Δ9-tetrahydrocannabinol in healthy humans. The International Journal of Neuropsychopharmacology October 2012
- Opioid antagonism enhances marijuana's effects in heavy marijuana smokers. Psychopharmacology August 2010
- Opioid antagonism of cannabinoid effects: differences between marijuana smokers and nonmarijuana smokers. Neuropsychopharmacology June 2007
- Involvement of mu-, delta- and kappa-opioid receptor subtypes in the discriminative-stimulus effects of delta-9-tetrahydrocannabinol (THC) in rats. Psychopharmacology June 2005
and 3 more in the library